{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.225","value":"-87.61"},{"groupId":"OG001","spread":"23.733","value":"-81.95"}]}],"title":"Week 5 Day 1 (Day 29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.810","value":"-88.06"},{"groupId":"OG001","spread":"32.261","value":"-85.45"}]}],"title":"Week 25 Day 1 (Day 169)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.235","value":"-88.23"},{"groupId":"OG001","spread":"12.088","value":"-87.56"}]}],"title":"Week 49 Day 1 (Day 337)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"description":"Blood samples were collected from participants for hormonal measurements.","dispersionType":"Standard Deviation","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"MEAN","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Week 5 Day 1 (Day 29), Week 25 Day 1 (Day 169), and Week 49 Day 1 (Day 337)","title":"Percent Change From Baseline In Serum Concentrations Of Dihydrotestosterone","type":"SECONDARY","unitOfMeasure":"percent change"}